Navigation Links
AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer

cinomas carrying the erlotinib-resistant mutation EGFR L858R/T790M. These in vivo results suggest that AV-412 may exert potent clinical activity against non-small cell lung cancer tumors harboring EGFR L858R or EGFR L858R/T790M mutations.

About AV-412

AV-412 is a next generation oral tyrosine kinase inhibitor of EGFR/HER2 that could potentially treat patients with solid tumors. In preclinical studies, AV-412 has shown excellent activity in various tumor models, has a toxicity profile similar to other molecules in its class, and has shown preclinical activity against tumor cells that are resistant to first-generation tyrosine kinase inhibitors. The targets of AV-412 have been implicated in many significant human cancers including non-small cell lung cancer, metastatic breast cancer, pancreatic cancer, head and neck cancer and hormone refractory prostate cancer. AVEO's proprietary Human Response Prediction(TM) Platform offers an opportunity to exploit AV-412's unique characteristics and will provide further insight into potential clinical settings, tumor subtypes and responsive patient populations. AVEO acquired worldwide rights outside of Asia to AV-412 from Mitsubishi Pharma Corporation. For more information on the AV-412 clinical trial, visit www.clinicaltrials.gov and search using the keyword AV-412.

About AVEO

AVEO is a private biopharmaceutical company focused on the discovery and development of novel, targeted cancer therapeutics. The company utilizes its proprietary, genetically-defined cancer models for the identification and validation of novel cancer targets, and has begun to build an impressive portfolio of drug discovery and development programs around these high-value targets. AVEO also uses its Human Response Prediction(TM) Platform to identify genetic profiles that correspond with patient responsiveness. AVEO expects to commence Phase 2 clinical studies by Q3-2007 for AV-951, its oral, second-generation VEGF receptor inhibit
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference

Post Your Comments:
(Date:11/9/2009)... N.Y., Nov. 9 /PRNewswire/ -- On Sept. 11, 2001,...her rescue workers came together to save as many l...hter Brian McCauley was one of those 9/11 first re... ,, Only in his late 30s, McCauley was diagnose...d extensive chemotherapy treatments, leaving him c...
(Date:11/9/2009)... Nov. 9 Women,s sexual health comp...ame to Viveve as it prepares for a 2010 launch of ...s. ,, "Viveve is a name that we believe capture...al health," said Kerry Pope, Viveve,s president an...pose of helping women restore their sense of fulfi...
(Date:11/9/2009).... 9 Boston Scientific Co... of its COGNIS® cardiac resynchronization the...ntable cardioverter defibrillator (ICD) in Japan. ...try of Health, Labor and Welfare (MHLW) in August ... COGNIS and TELIGEN are the result of a multi-year...
Breaking Medicine Technology:The SCOOTER Store Surprises 9/11 First Responder & Merrick Firefighter With Power Chair 2The SCOOTER Store Surprises 9/11 First Responder & Merrick Firefighter With Power Chair 3Women's Sexual Health Company Changes Name in Preparation for Market Entry 2Boston Scientific's Most Advanced Devices to Treat Heart Failure and Sudden Cardiac Death Now Available in Japan 2Boston Scientific's Most Advanced Devices to Treat Heart Failure and Sudden Cardiac Death Now Available in Japan 3Boston Scientific's Most Advanced Devices to Treat Heart Failure and Sudden Cardiac Death Now Available in Japan 4The Quigley Corporation Updates and Amends By Laws and Rights Agreement 54783 1The Quigley Corporation Updates and Amends By Laws and Rights Agreement 54783 2The Quigley Corporation Updates and Amends By Laws and Rights Agreement 54783 3Update 3A Medicare Picks N J to Test Innovative Incentive System 54779 1Update 3A Medicare Picks N J to Test Innovative Incentive System 54779 2What Oklahomans Should Know About Cataract Surgery 54775 1What Oklahomans Should Know About Cataract Surgery 54775 2What Oklahomans Should Know About Cataract Surgery 54775 3
...O Annual Meeting Will Further Demonstrate, the S...iple Myeloma -, CAMBRIDGE, Mass., May 16 Millenn...oday announced that new data from VELCADE,clinical...American Society,of Clinical Oncology (ASCO) Annua...008. The data will highlight the significant effic...
...harmaceuticals,Corp. (Nasdaq: MEMY ) today announ... at its R&D Day meeting with the investment commun...M 1414, its lead PDE4 inhibitor,demonstrating the ...e,Company has nominated MEM 68626 as the lead deve...m, and separately confirmed its 2008 development,g...
Other Medicine Technology:New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 2New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 3New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 4New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 5New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 6New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 7New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 8Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day 2Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day 3Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day 4
(Date:11/10/2009)... BoxTone(R), the expert in mobile user manage...ite to manage, track and control enterprise smartp...rating system. The announcement follows last month... included new support for other ActiveSync-attache...e and Windows Mobile. , C...
(Date:11/10/2009)... Using an ultrasonic cleaner is faster, safer...dical instruments used in healthcare facilities. I...d lower costs through reuse of instruments are add... South Orange, NJ (PRWEB) November 10,... of medical instruments is a critical step in prev...
(Date:11/10/2009)... It is now possible to achieve exceptionally ...osed of hard materials such as ceramics, carbide a...th the new Diamond Flex-Hone® honing tool fr... Los Angeles (PRWEB) November 10, 2009 -- Us...bedded to the ends of flexible filaments, the Diam...
(Date:11/10/2009)... Carrington Nuamah, P.C., a Seattle law firm ...n and estate law, has unveiled a new website. Res... learn more about the firm at www.carringtonnuama...xis Nexis) November 10, 2009 -- Seattle Law Firm C...at www.carringtonnuamah.com . Lawyers Andrew Car...
(Date:11/10/2009)...versity Rollins School of Public Health researcher... American Public Health Association,s annual meeti...d compliance with national recommendations that a ...utes of their arrival to the Emergency Department ...gs from Emory scientists are highlighted below. ,...
Breaking Medicine News(10 mins):Health News:BoxTone Delivers Enterprise Mobile User Management for Google Android 2.0 Smartphones 2Health News:BoxTone Delivers Enterprise Mobile User Management for Google Android 2.0 Smartphones 3Health News:Ultrasonic Cleaner from Tovatech Plays Key Role in World Health Organization's Guidelines for Infection Control 2Health News:Ultrasonic Cleaner from Tovatech Plays Key Role in World Health Organization's Guidelines for Infection Control 3Health News:Diamond Honing Tool Technology: The New Standard in Surface Finishing of Hard Materials 2Health News:Seattle Law Firm Carrington Nuamah Launches New Website for Personal Injury, Bankruptcy, Immigration and Estate Law 2Health News:Some chest pain patients wait longer than 10 minutes to see ER physician 2
... are of the opinion that the Police have become th... inadequacy of prevalent services and support mech...mment follows close on the heels of an incident, w...the frontline of mental health services," Mr Cheve...
...cil of Medical Research has announced the installa...ies by ICMR in Chennai// , New Delhi, Kolkata and ... An international consultancy firm will be in ...ancial year. A centre of this type has already bee...
...at 6.5 billion and will touch the seven billion m... Time, reported the science portal Live Science. ...ulation every second, the world will be home to se...orld population hit the six billion mark in June 1...
... after announcement of Bird Flu in India .In Gujar...n wiped out. In Utchal taluka of Surat 90,000 c...retary of the Gujarat Broiler Farmers' Association...poultry products across the state except a small p...
...has completely changed. Chinese are experimenting ... (LAT). In this one can life the life of a married...partner does not desires to stay together and that... if one of them refuses, the other would not force...
... foods in the cereal category as they provide fibr...rt of health-conscious consumers. So there is news...luble oat fiber called beta-glucan in their diets.... can help lower blood levels of so-called "bad" ch...
Other Medicine News:Health News:Sex a commonplace in Chinese life 2
SLM 4000 Autolensmeter
CL-100 4.0 Computerized Lensmeter
Pro-lll
FF 450plus Iru
Medicine Products: